EFFECTS OF LOW MOLECULAR WEIGHT AND UNFRACTIONATED HEPARIN ON LIPOPROTEIN LIPASE AND LIPID PROFILE IN HAEMODIALYSIS PATIENTS

Ahmad Jan¹, Shah Jahan¹, Nighat Aziz², Sikandar Ali Khan², Asia³, Zarghuna Zeb³, Amir Afzal Khan⁴

Submitted: February 02, 2021  
Accepted: April 23, 2020  
Published: June 30, 2021

Authors’ Affiliation  
¹Gomal Medical College, Medical Teaching Institute, Dera Ismail Khan, Pakistan  
²Khyber Medical University, Peshawar, Pakistan  
³Peshawar Medical College, Peshawar, Pakistan  
⁴Khyber College of Dentistry, Peshawar, Pakistan  
⁵Iqra National University, Peshawar, Pakistan

Corresponding Author  
Amir Afzal Khan  
Department of Allied Health Sciences, Iqra National University, Peshawar, Pakistan  
E-mail: amirafzal98@gmail.com

ABSTRACT

Introduction: In haemodialysis patients, mortality from cardiovascular disease is much greater than in the general population. The current study aimed to evaluate the effects of two different types of heparin, low molecular weight heparins (LMWH) and high molecular weight heparin (HMWH), on lipid profile in patients undergoing haemodialysis.

Material & Methods: A total of 60 patients on haemodialysis were selected from two main hospitals of Lahore, Pakistan and were divided into two major groups based on the type of heparin used. A 5 ml blood sample was taken from the dialysis machine to get the serum and was kept frozen at -20°C for analysis of total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein. Comparison of lipoprotein lipase activity between groups were evaluated by using the student t-test. A P-value of ≤ 0.05 was considered statistically significant.

Results: Gender wise distribution of study population (n=60) was 67% (n=40) males and 33% (n=20) females. The age distribution of individuals varied from 39-43 years. Moreover, use of HMWH was high in males (73%) as compared to females (27%) with an average age of 39 ± 12 years where duration of haemodialysis was 4.44 ± 2.83. A significant difference in LPL activity related to different times in all patients was observed. A clearer difference observed in case of LDL where LPL activity was markedly different in both groups. Our data showed that individuals using LMWH had less chances of dyslipidaemia as compared to those using HMWH.

Conclusion: LMWH is a useful and safe anticoagulant during haemodialysis as compared to HMWH.

Key Words: Lipoprotein Lipase, Heparin, Haemodialysis.

INTRODUCTION

Cardiovascular disease is a leading cause of morbidity and mortality among dialysis patients and accounts for half or more of the deaths. The increased risk of cardiovascular events in haemodialysis (HD) patients not only includes high blood pressure, diabetes mellitus, increased concentration of lipids in the blood, increased use of tobacco, and lack of physical activity but also included use of heparin and metabolic disturbances associated with renal dysfunction. Renal-associated risk factors are renal dyslipidaemia, increased lipoprotein A levels, increased homocysteine level in the blood, decreased albumin level in the blood, hemodynamic disturbance and anemia. In the early 1960s, HD was started for treating renal failure patients and the risk of clotting in extracorporeal devices was reduced to a minimum by use of heparin. The pharmacodynamics of unfractionated heparin (UFH) vary among patients. Usually a loading dose of approximately 50 IU/Kg body weight, followed by infusion of 800-1500 IU/hr is recommended for routine anticoagulation. During the past few years, various low molecular weight heparin (LMWH) is increasingly used for HD. The main advantage of these are their easy administration and a reduced increase in lipoprotein lipase (LPL) activity, reflecting the decreased effect on lipoproteins as compared to UFH. In early study heparin was used as an initial bolus dose and then followed by continuous infusion. As LMWH preparations have longer effects on anticoagulation, a single bolus injection before dialysis is now recommended even in dialysis sessions of five hours. Molecular weight of UFH varies between 5,100 and 29,900 Dalton. Reticuloendothelial system is the most important system regarding the breakdown of UFH, however, small amount passes in the urine as such. Average half-life of UFH is normally around 55 minutes and this may be prolonged in individuals with end-stage renal failure. Protamine can be used to neutralize the anticoagulant effects of UFH and is given in the form of slow intravenous (IV) infusion. Bleeding, dyslipidaemia and abnormal hepatic function tests are the most common complications associated with the use of UFH.

For the last few years, several types of LMWH are used in hospitals. LMWH is composed of segments of UFH which are formed by de-polymerization methods. These segments usually have a molecular weight of 1,000-10,000 Dalton, with a mean of 4500-5000 Dalton. When administered IV, LMWH has two times longer duration of action as anticoagulant than UFH. LMWH unlike UFH is metabolized by kidneys. In contrast
to UFH, the anticoagulant effects of LMWH cannot be reversed by the use of protamine. LMWH is less associated with bleeding complications as compared to UFH. The current study aimed to evaluate the effects of two different types of heparin that are LMWH and UFH also called high molecular weight heparin (HMWH) on lipid profile in haemodialysis patients.

**MATERIAL AND METHODS**

Study subjects (n=60) both males and females were divided into two main groups (A and B) based on types of heparin used and each main group was divided into two subgroups (I and II) based on age. The criteria for inclusion were patients on HD for at least two months. Patients with ischemic heart diseases, carcinomas, and lymphomas were excluded from the study. Patients from Sheikh Zayed Hospital were using HMWH and those from Mayo Hospital were using LMWH. All patients participated willingly with prior written consent to undergo tests and examinations. History of the patients, demographic information, and biochemical findings were recorded in the prescribed proforma.

A 5 ml whole blood sample was taken in disposable syringes from one of the ports of the dialysis machine and placed in a plastic tube and clot properly and get serum after passing through centrifugation and clear serum obtained was placed in tubes and kept frozen at -20°C for analysis of total cholesterol (TC), triglycerides (TGs), High-density lipoprotein (HDLC) and Low-density lipoprotein (LDLC). This whole procedure was applicable for baseline (0 minutes, at pre-dialysis) and consequent levels (15, 30, 60, 120, 180 minutes of dialysis) of LPL and other lipid tests.

**Statistical Analysis**

Statistical analysis was done on SPSS 20.0. Data for age, duration since on HD, LPL, and lipid profile (Total cholesterol, Triglyceride, HDL cholesterol, LDL cholesterol) for various times during dialysis was described by using Mean ± SD for both groups. A p-value of ≤ 0.05 was considered statistically significant.

**RESULTS**

Blood samples from 60 patients on haemodialysis were collected from two main hospitals in Lahore. Out of the total, according to gender distribution, 67% (n=40) individuals were males and 33% (n=20) were females (Table 1). Gender wise distribution of use of low molecular weight heparin (LMWH) was high in male (60%, n=18) individuals as compared to female (40%, n=12) with an average age of 42 ± 14 years with a 2.81 ± 2.99 duration of haemodialysis. Moreover, use of high molecular weight heparin (HMWH) was high in males (73%, n=22) as compared to female (27%, n=8) with an average age of 39 ± 12 years with 4.44 ± 2.83 duration of haemodialysis (Table 1). As far as whole study population was concerned, the use of LMWH and HMWH was equally distributed. Comparison of LPL activity between two main and two sub-groups was evaluated by using a student t-test. Based on statistical analysis there was a significant difference in LPL activity related to different times in all patients (Figures 1-4). More clear difference was observed in LDL where LPL activity was markedly different in both groups (Figure 4). In conclusion, results of the study showed that there were fewer chances of dyslipidaemia in individuals using LMWH as compared to those using UFH or HMWH.

**DISCUSSION**

In our study, the effects of heparin were determined between two main groups (A and B), there was a significant difference in LPL activity (P<0.05) with time except between 15-30 minutes. These findings are in close agreement with the study reported previously.13

In the present study, the result of total cholesterol between the two main groups was statistically nonsignificant having a p-value > 0.05 and such observations were seen in another study from Sweden.14 Another study from Riyadh, Saudi Arabia, reported that fewer chances of dyslipidaemia occur with low molecular weight heparin.15 Another study from Egypt16 also recorded that as compared to unfractionated heparin, the low molecular weight was effective and found statistically significant. This study’s findings are in agreement with the current study. The present study revealed that the levels of triglycerides were low from baseline to 60 minutes after giving LMWH and was statistically significant (P < 0.05) in group A as compared to group B (receiving HMWH) where a decrease in triglyceride level was observed from baseline to 15 minutes and was significant (P < 0.05). Similar results were observed in another study from Sweden reported previously14 which support our current study findings.

In the current study, levels of HDL cholesterol (considered to be good lipoproteins) rises from baseline to 30 minutes (P <0.05) in group A receiving low LMWH patients while in group B patients there was no significant rise in HDL cholesterol, rather a fall in HDL cholesterol levels from 120 minutes to 180 minutes (P <0.05) was observed. These findings correlate with the findings of studies conducted previously.16 In the present study, levels of LDL cholesterol (considered to be the bad lipoproteins) rises significantly (P <0.05) only from baseline to 15 minutes in group A patients receiving LMWH while LDL cholesterol level raised significantly (P <0.05) from baseline to 120 minutes. These findings were also observed in a previous study.14

Previous study investigations from the USA17 supports our current study findings as LMWH used safe in chronic haemodialysis patients. Another study from Iran reported that LMWH was an effective and safe anticoagulant for haemodialysis patients.18 Same results were observed in this study and were supported by other previous studies.19,20

Majority of the studies showed a decrease in lipid levels using LMWH except for three which reported either an increase or no changes for cholesterol,21,22 LDL-cholesterol,21,23 and triglycerides.22,23 Findings of these studies are not similar to the current study findings. The European Best Practice Guidelines for haemodialysis recommended the use of LWMM yet another study reported that UFH remained the most frequent choice for treatment of haemodialysis patients in North America.24 The cost may be the main argument for not using LMWH in haemodialysis and their safety remains a major concern. These findings are not similar to the current study, as the current study reported that LMWH is safe in haemodialysis patients. Both hepatic and renal pathways metabolized the UFH by but LMWH is mainly through kidneys leading to potential bioaccumulation and arises risk of haemorrhage.25

Another study conducted by Lim et al. which reported...
the efficacy and safety of LMWH in hemodialysis had the same results as observed in the current study.

CONCLUSION

Low molecular weight heparins (LMWH) are a better, useful, and safe anticoagulant for haemodialysis patients. LMWH has positive effects on HDL considered to be the best lipoprotein in the human body in contrast to LDL. Larger studies are needed to evaluate properly the safety of LMWH haemodialysis patients.

REFERENCES

1. Yukawa S, Mune M, Yamada Y, Otani H, Kishino M, Tone Y. Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Kidney International. 1999 Jul 1;56: S141-3.
2. Locatelli F, Marcelli D, Conte F, D Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrology Dialysis Transplantation. 2000 Oct 2;15(90005):69-80.
3. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrology, dialysis, transplantation (Print). 2000; 15:58-68.
4. Lazarus JM, Denker BM, Owen JR. WF: Hemodialysis in The kidney (vol 2), edited by Brenner BM, 5ed, Philadelphia, W.B. Saunders Company, 1996; pp 2424-5
5. Majerus PW. Anticoagulant, thrombolytic, and antiplatelet drugs. Goodman and Gilman’s the pharmacological basis of therapeutics. 2001:1519-38.
6. Kessler M, Canaub D, Pedrini LA. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 17 Suppl 2002; 7:63-71
7. Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Fauchald P, Brostad F. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrology Dialysis Transplantation. 1999 Aug 1;14(8):1943-7.
8. Schrader J, Andersson LO, Armstrong VW, Kundt M, Stibbe W, Scheler F. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. In Seminars in thrombosis and hemostasis 1990 Oct 1 (Vol. 16, pp. 41-45).
9. Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clinical nephrology. 1989 Dec 1;32(6):290-6.
10. Holmer E. Low molecular weight heparin, in Heparin; Chemical and Biological Properties, Clinical Applications, edited by Lane DA, Lindahl U, London, England, Edward Arnold Publishers Ltd, 1989; pp 575-95
11. Lai KN, Ho K, Li M, Szeto CC. Use of single dose low-molecular-weight heparin in long hemodialysis. The International journal of artificial organs. 1998 Apr;21(4):196-200.
12. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001 Jan 1;119(1):64S-94S.
13. Naasström B, Stegmayr BG, Olivecrona G, Olivecrona T. Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. Journal of Laboratory and Clinical Medicine. 2003 Aug 1;142(2):90-9.
14. Näsström B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrology Dialysis Transplantation. 2005 Jun 1;20(6):1172-9.
15. Al-Saran KA, Sabry A, Taha M, Ghafour MA, Al Fawzan F. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis. Saudi Journal of Kidney Diseases and Transplantation. 2010 Jan 1;21(1):43.
16. Park JW, Jeon OC, Kim SK, Al-Hilal TA, Jin SJ, Moon HT, Yang VC, Kim SY, Byun Y. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives. Journal of controlled release. 2010 Dec 20;148(3):317-26.
17. Shantha GP, Kumar AA, Sethi M, Khanna RC, Panchoy SB. Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis. PeerJ. 2015 Mar 10;3:e835.
18. Tabibian S, Rahbar K, Ghadrdooost B, Zahed NS, Falaknaz K, Piraste H. Comparison of enoxaparin sodium and standard heparin for hemodialysis anticoagulation. Nephro-Urology Monthly. 2017 Mar 31;9(2).
19. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. Journal of the American Society of Nephrology. 2004 Dec 1;15(12):3192-206.
20. Abdallah E, Mosbah O, Khalifa G. Assessment of the administration of low molecular weight heparin for hemodialysis anticoagulation in comparison to standard unfractionated heparin. Journal of Advances in Medicine and Medical Research. 2015 Jan 10;867-74.

21. Kronenberg F, König P, Lhotta K, Steinmetz A, Dieplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clinical nephrology. 1995 Jun 1;43(6):399-404.

22. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Köstering H, Seidel D, Scheler F. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney international. 1988 Apr 1;33(4):890-6.

23. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrology Dialysis Transplantation. 1999 Nov 1;14(11):2698-703.

24. Group EB. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2002; 17:63-71.

25. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001 Jan 1;119(1):64S-94S.

26. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. Journal of the American Society of Nephrology. 2004 Dec 1;15(12):3192-206.

Table 1: Gender, age and duration of haemodialysis of patients using types of heparin

| Types of heparin                      | Male | Female | Age ± SD | Duration of haemodialysis ± SD |
|--------------------------------------|------|--------|----------|-------------------------------|
| Low molecular weight heparin         | 18   | 12     | 42±14    | 2.81±2.99                     |
| High molecular weight heparin        | 22   | 08     | 39±12    | 4.44±2.83                     |

Figure 1: Pattern of total cholesterol with times after use of LMWH and HMWH

Figure 2: Pattern of triglycerides with times after use of LMWH and HMWH

Figure 3: HDL with after use of LMWH and HMWH

Figure 4: LDL with use of LMWH and HMWH